Lisa Wipperman Heine, COO of Mitralign, says the FDA is making quicker work of review times. But the same might not be said for other countries where Medtechs once had a faster time to market. In this interview at the offices of Fox Rothschild in Minneapolis, the Medtech veteran lays out Mitralign’s success with the agency’s Early Feasibility program.